Navigation Links
ViaCyte Appoints Mark Foletta, former CFO of Amylin, to its Board of Directors
Date:12/19/2013

SAN DIEGO, Dec. 19, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that Mark G. Foletta has been appointed to its Board of Directors.

(Logo: http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a)

Mr. Foletta is a seasoned financial executive with over 30 years of corporate experience.  He was most recently senior vice president and Chief Financial Officer at Amylin Pharmaceuticals, Inc.  He joined Amylin in 2000 and served through its acquisition by Bristol-Myers Squibb for approximately $7 billion in August 2012.  During his time at Amylin the company grew from 75 to over 1,300 employees and he was instrumental leading numerous strategic transactions with global pharmaceutical companies, as well as public and private financing transactions.  As chair of Amylin's Operating Committee, he had responsibility for business planning, forecasting and assessing performance.  He also participated in the commercial launch of three novel pharmaceutical products that generated annual revenues reaching over $700M. 

Prior to Amylin, Mr. Foletta worked 14 years at Intermark, Inc./Triton Group Ltd. where he served as senior vice president, Chief Financial Officer and Corporate Secretary.  Mark began his career in 1982 as an Audit Manager at Ernst & Young, LLP in San Diego.  He holds a B.A. in Business Economics and is a Certified Public Accountant (currently inactive).  

"We are pleased to welcome Mark to our Board of Directors," said Paul Laikind, Ph.D., ViaCyte's president and Chief Executive Officer.  "With our promising cell replacement therapy for type 1 diabetes, the VC-01™ combination product, expected to enter the clinic next year, we will be exploring the new strategic and/or financial transactions that will continue to fuel our growth.  Mark's many years as a senior finance executive, including 12 years in the biotechnology sector with a company focused on diabetes, will undoubtedly serve us well as we navigate our way to success."

"I am looking forward to working closely with the team at ViaCyte," said Mr. Foletta.  "VC-01 holds the promise of transforming the way patients with type 1 diabetes manage their disease.  In fact, if VC-01 performs in humans as it has in animal studies, it could effectively cure the disease for patients with type 1 diabetes and be an important new therapy for those patients with insulin-dependent type 2 diabetes as well.  It is an exciting time for the company and I am pleased to lend my expertise."

Fred Middleton, ViaCyte's Chairman of the Board said, "On behalf of the board and management of ViaCyte, I want to join Paul in welcoming Mark to the team."

ViaCyte has held productive meetings with the United States Food and Drug Administration (FDA) and Health Canada and is on track to file an Investigational New Drug (IND) Application to support the initiation of clinical evaluation of the VC-01 combination product in patients with diabetes in mid-2014. 

About ViaCyte

ViaCyte is a private company focused on developing a novel cell therapy for the treatment of diabetes. The Company's technology is based on the production of pancreatic beta cell progenitors derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device. Once implanted and matured, these cells secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte's goal is long term insulin independence without immune suppression, and without risk of hypoglycemia and other diabetes-related complications.

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.

This news release may contain forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995.

 


'/>"/>
SOURCE ViaCyte
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ViaCyte Receives $10.1 Million Strategic Partnership Award from CIRM to Continue Development of Diabetes Therapy
2. ViaCyte, Inc. raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes
3. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
4. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
5. Nephros Appoints John C. Houghton as President and Chief Executive Officer
6. Elsevier Appoints New President of Elsevier CPM Resource Center
7. GenWay Biotech Appoints New Vice President of Custom/OEM
8. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
9. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Hill-Rom Appoints Alton Shader President of Hill-Rom North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... June 5, 2017 The Cincinnati ... Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded a ... . Results are based on an employee survey ... health and workplace improvement. The survey measures several aspects of ... ...
(Date:5/30/2017)... , May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... data solutions, today announced that it will be presenting at the ... 8:00 AM PT. Erez Raphael , CEO, of DarioHealth will ... conference will be held on June 6th & 7th, 2017 at ... in the small / micro-cap space. ...
(Date:5/26/2017)... 25, 2017  In response to the opioid epidemic ... Relief is working with Pfizer to make up to ... cost to community health centers, free and charitable clinics, ... "Pfizer has a long-standing commitment to improving ... patient safety through educational activities," said Caroline Roan ...
Breaking Medicine Technology:
(Date:6/27/2017)... Simi Valley, CA (PRWEB) , ... June 27, 2017 , ... ... deployed since 2001 suffer from PTSD. Yet less than 20% will receive adequate care ... of those with PTSD won't receive any care at all. And left untreated, veterans ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... Antoine Dental Center is now ... standard in tooth replacement and act as a support for prosthetic teeth, such as crowns, ... the existing bone and becomes a sturdy, lasting new root for the tooth. , ...
(Date:6/26/2017)... Lake Tahoe, CA (PRWEB) , ... June 26, 2017 , ... ... seeking 10,000 qualified mental health professionals in every state across the country to join ... an easy and rewarding way for therapists to reach a substantially greater number of ...
(Date:6/25/2017)... ... , ... Create a feel-good lyric music video in Final Cut Pro X with ProLyric from ... write in the lyrics to any song. ProLyric flies in the text for each section ... can be added modularly for optimal control. ProLyric makes editing any music video or text-based ...
(Date:6/25/2017)... , ... June 25, 2017 , ... June is Men’s Health Month and ... most common cancer among men in the U.S. and the third most common cause of ... estimated that one man in seven will be diagnosed with prostate cancer during his lifetime. ...
Breaking Medicine News(10 mins):